Clinical Report: Evaluation of Serum Levels of miR-21, VEGF, and CA15-3 for Breast Cancer Diagnosis
Overview
This study evaluates the diagnostic utility of serum miR-21 in breast cancer, comparing it to traditional biomarkers VEGF and CA15-3. Results indicate that miR-21 demonstrates superior sensitivity and specificity for distinguishing breast cancer from benign conditions and healthy controls.
Background
Breast cancer remains a leading cause of cancer-related morbidity and mortality globally. Early detection is crucial for improving treatment outcomes, yet current serum biomarkers like CA15-3 and VEGF have limitations in sensitivity and specificity. This study investigates miR-21 as a potential non-invasive biomarker for early breast cancer diagnosis.
Data Highlights
Biomarker
AUC
Sensitivity
Specificity
miR-21 (BC vs Healthy)
0.897
81.10%
98.40%
miR-21 (BC vs Benign)
0.842
76.40%
98.60%
Key Findings
Serum levels of miR-21, VEGF, and CA15-3 were significantly elevated in breast cancer patients compared to healthy controls (p<0.05).
miR-21 and CA15-3 levels were higher in breast cancer patients than in those with benign nodules (p<0.05).
No significant correlations were found between miR-21 and VEGF or CA15-3 in the breast cancer cohort.
miR-21 showed an AUC of 0.897 for distinguishing breast cancer from healthy individuals.
miR-21's diagnostic performance surpassed that of VEGF and CA15-3.
Limitations include a small sample size and a single-center design, necessitating further validation.
Clinical Implications
The findings suggest that serum miR-21 could serve as a promising non-invasive biomarker for early breast cancer detection, potentially aiding in the differentiation of malignant from benign lesions. However, further studies are required to validate these results in larger, multicenter cohorts.
Conclusion
Serum miR-21 demonstrates significant potential as a diagnostic biomarker for breast cancer, outperforming traditional markers. Future research should focus on validating these findings and exploring miR-21's role in clinical outcomes.
